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CCL21 is a homeostatic lymphoid chemokine instru-
mental in the recruitment and organization of T cells
and dendritic cells into lymphoid T areas. In human
secondary lymphoid organs (SLOs), CCL21 is pro-
duced by cells distributed throughout the T zone,
whereas high endothelial venules (HEVs) lack CCL21
mRNA. A critical question remains whether the devel-
opment of ectopic lymphoid tissue (ELT) in chronic
inflammation recapitulates the features of SLOs.
Thus, we systematically investigated in situ the cellu-
lar sources of CCL21 in SLOs and ELTs in several
human diseases characterized by lymphoid neogene-
sis. By in situ hybridization and the use of combina-
torial cell markers, we show that CCL21-producing
vessels in inflamed tissues systematically display typ-
ical markers of lymphatic vessels, whereas, as in
SLOs, ectopic HEVs do not synthesize detectable levels
of CCL21. We also provide first-time evidence that a
common pattern of CCL21 expression by CD45-nega-
tive myofibroblast-like cells localized in extra-HEV
position and organized in a fibroblastic reticular net-
work similarly characterizes human SLOs and orga-
nized ELTs. Altogether, our results demonstrate that
in humans the pattern of CCL21 production in SLOs
is maintained during inflammation and that the
phenotypic and functional properties of stromal
cells , found in SLO T-cell areas , are reproduced at
ectopic sites. (Am J Pathol 2007, 171:1549–1562; DOI:
10.2353/ajpath.2007.061275)
CCL21 is a homeostatic chemokine constitutively pro-
duced in secondary lymphoid organs (SLOs) where it
is involved in CCR7 naı¨ve and central memory T-cell
homing via high endothelial venules (HEVs). CCL21 is
also instrumental in the topographical compartmental-
ization of T cells with CCR7 mature antigen-bearing
dendritic cells (DCs) in the T-cell area.1–3 Here, CCL21
directly participates to the immunological synapsis,
promoting T-cell co-stimulation in trans by means of a
chemokine-mediated tethering and priming on DCs.4
Alongside its constitutive function in SLOs, CCL21 is
also sufficient to mediate naı¨ve cell extravasation in
nonlymphoid inflamed tissues5 and to promote the
constitution of ectopic lymphoid tissue (ELT) in trans-
genic mice.6–8 Accordingly, increased expression of
CCL21 is strongly associated to the development of
lymphoid-like structures in chronically inflamed human
tissues, including the joint synovium in rheumatoid ar-
thritis (RA), salivary glands in Sjo¨gren’s syndrome (SS),
and the intestinal mucosa in ulcerative colitis (UC) and
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Crohn’s disease (CD). For a review, see Aloisi and Pujol-
Borrell.9 Suggesting that CCL21 constitutive function may
be ectopically reprogrammed in inflammation, CCL21-ex-
pressing cells in ELTs have been shown to compartmental-
ize with T-cell-rich areas and with mature DCs.10–13
Although these observations indicate the existence of
a functional partnership between CCL21-producing cells
with T cells and DCs in the genesis of adaptive re-
sponses, a comprehensive characterization of CCL21-
producing cells in human lymphoid tissue has not been
performed. It is thus unclear whether and to what extent
inflammation influences the pattern of CCL21 expression
in ELTs or whether the same cellular sources are respon-
sible for CCL21 production in SLOs and ELTs.5,13,14
Although CCL21 is constitutively expressed in murine
SLOs by T-zone stromal cells,15 lymphatic vessels, and
HEVs16 as an expression of a species-specific differ-
ence, we and others have recently demonstrated that
human SLO HEVs lack CCL21 mRNA.10,17 Instead, the
chemokine is produced by lymphatics and nonendothe-
lial cells (non-ECs) within the T area,17 and translocation
of the protein through HEVs has been surmised to medi-
ate T-cell homing,17 in keeping with the process of trans-
cytosis previously demonstrated for CCL19.18 Con-
versely, as opposed to the extravascular synthesis of
CCL21 in human SLOs, in inflamed peripheral tissues it
has been suggested that CCL21 may be aberrantly in-
duced in ECs of blood vessels and some HEVs, misdi-
recting naı¨ve T cells to sites of inflammation and trigger-
ing the early events of lymphoid neogenesis.5 Thus,
CCL21 production in inflammation would involve specific
endothelial differentiation or activation pathways not
shared by SLOs and potential target of selective thera-
pies. However, CCL21 is also constitutively produced by
lymphatic vessels in peripheral tissues,5,16,19 where it
mediates mature DC and T-cell entry into afferent lym-
phatics, allowing their migration to draining lymph nodes
(LNs).20–23 Importantly, CCL21-mediated exit through
the lymphatics has been shown to be amplified both in
experimental inflammation24 and in human skin inflam-
matory diseases.25 In keeping with this concept, CCL21
lymphatic vessel neoangiogenesis has been described in
association with the development of ectopic lymphoid ag-
gregates in renal rejection,26 indicating that the constitutive
cellular sources of CCL21 in peripheral tissues and SLOs
can participate in CCL21 production in human ELTs.
To clarify whether chronic inflammation is associated
with the appearance of novel sources of CCL21, or rather
the pattern of the chemokine is conserved in secondary
and ectopic locations, we performed a comparative ex-
pression analysis of CCL21 in human SLOs and in a
subset of chronic diseases in which immune cells accu-
mulate and form ELTs, addressing the cellular sources of
CCL21 in its constitutive environment and in inflammatory
sites. We show that the lymphatic system is the source of
endothelial CCL21 in inflamed peripheral tissues and
that, as in SLOs, blood vessels or HEVs do not synthesize
detectable levels of the chemokine in ELTs. We also
show, to our knowledge for the first time, that the extra-
endothelial expression of CCL21 by smooth muscle ac-
tin-positive (SMA) stromal cells is a conserved feature in
human SLOs and ELTs.
Materials and Methods
Tissues
Synovial samples for in situ hybridization, immunohisto-
chemistry (IHC), and immunofluorescence (IF) were ob-
tained from a total of 27 RA patients fulfilling the American
College of Rheumatology 1987 revised criteria27 under-
going joint replacement, synovectomy, or arthroscopic
biopsy. The immunophenotypic analysis of CCL21-ex-
pressing cells was extended to other inflammatory le-
sions including minor salivary glands from SS (n  21
patients), intestinal biopsies from UC (n  10 patients)
and CD (n 6 patients), and skin biopsies from psoriasis
(n  4 patients) and lichen planus (n  3 patients).
Patient data, histopathological grading, and treatment
schedules are provided in Table 1. Control materials
consisted of various normal human SLOs, including
two human tonsils, two human mesenteric lymph nodes
(MLNs), two cervical lymph nodes (CLNs), two axillary
lymph nodes (ALNs), and one human spleen, obtained
from individuals undergoing tonsillectomy, surgical re-
section for neck, colon, or mammary cancer or surgical
resection for abdominal trauma. All LNs were free from
cancer metastasis. The constitutive pattern of CCL21
expression was also investigated in noninflamed pe-
ripheral tissues, including two normal synovial tissues
collected during lower limb amputation, two normal
minor salivary glands obtained from individuals with
suspected amyloidosis28 (normal histology assessed
by routine examination; Congo red-negative), one nor-
mal colon obtained during surgical resection for can-
cer at a minimum of 5 cm from the tumor (normal
histology assessed by routine examination), and one
normal skin sample obtained from mastectomy. All tis-
sues were fixed in formalin and embedded in paraffin.
Four additional RA synovial samples selected for the pres-
ence of lymphoid aggregates and HEVs, two human tonsils,
and one MLN were embedded in OCT and snap frozen in
liquid nitrogen for comparative staining analysis with paraf-
fin-embedded tissues. All procedures involving patient ma-
terial were approved by the local ethics committee (code
no. 08004598/b).
In Situ Hybridization
35S-labeled sense and anti-sense RNA probes were gen-
erated by in vitro transcription (Roche Molecular Bio-
chemicals, Indianapolis, IN). The human CCL21 probe
corresponded to positions 6 to 368 of the CCL21 se-
quence (accession number AB002409).29 Hybridization
and detection of the hybridized probe were performed as
previously described.10,30
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IHC
IHC on paraffin-embedded tissue sections was per-
formed as previously described in detail.10,30 The fol-
lowing primary antibodies were used: goat anti-human
CCL21 (IgG; R&D Systems, Minneapolis, MN), mouse
anti-human CD31 (IgG1, clone 1A10; Novocastra,
Newcastle-on-Tyne, UK), mouse anti-human CD34
(IgG1, clone QBEnd/10; Novocastra), rat anti-human/
mouse peripheral lymph node addressin (PNAd) (IgM,
clone MECA 79; PharMingen, San Diego, CA), mouse
anti-human lymphatic vessel endothelial hyaluronan
receptor (LYVE-1) (IgG1, clone 8C; provided by D.G.
Jackson, Institute for Molecular Medicine, John Rad-
cliffe Hospital, Oxford, UK), goat anti-human LYVE-1
(IgG; R&D Systems), mouse anti-human podoplanin
(IgG1, clone 4D5aE5E6; Bender MedSystems, Wien,
Austria), rat anti-human D6 (IgG2a, clone 196124; R&D
Systems), rabbit anti-human CD3 (IgG; DAKO, Carpin-
teria, CA), mouse anti-human CD20 (IgG2a, clone L26;
DAKO), mouse anti-human CD21 (IgG1, clone 1F8;
DAKO), goat anti-human CXCL13 (IgG, R&D Systems),
goat anti-human CCL19 (IgG, R&D Systems), mouse anti-
human DC-lysosome-associated membrane protein
(LAMP) (IgG1, clone 104-G4; Immunotech, Marseilles,
France), mouse anti-human CD45 (IgG1, clones 2B11 
PD7/26; DAKO), and mouse anti-human SMA (IgG2a,
clone 1A4; DAKO). Negative staining control experiments
were performed either by omitting the primary antibody or
by using a control isotype-matched antibody. For double-
staining experiments, dewaxed and rehydrated sections
were heated at 96°C in target retrieval solution (DAKO),
washed in Tris-buffered saline (TBS), and incubated with
Protein Block Serum Free (DAKO). The first primary anti-
body was applied, followed by incubation with peroxi-
dase-conjugated rabbit anti-mouse IgG (DAKO). Sec-
tions were then developed using 3,3-diaminobenzidine
tetrahydrochloride (Sigma, St. Louis, MO), blocked in dis-
tilled water, washed in TBS, and again incubated in Protein
Block Serum Free. The second primary antibody was ap-
plied, followed by incubation with biotinylated donkey anti-
goat IgG (Jackson ImmunoResearch Laboratories, Cam-
bridgeshire, UK) and amplification with streptavidin biotin
complex-alkaline phosphatase (DAKO). Sections were de-
veloped using New Fuchsin substrate kit (DAKO), counter-
stained with Meyer’s hematoxylin (Merck, Rahway, NJ) and
mounted with Aquamount mounting medium (BDH, Poole,
UK). Primary and secondary antibodies were diluted in
DAKO antibody diluent.
IF
Double-color IF for CCL21 and PNAd was performed
on OCT-embedded frozen samples of four RA synovial
membranes, two human tonsils, and one human MLN.
Six-m-thick sections were cut, allowed to dry on glass
slides, and fixed for 15 minutes in acetone. Sections
were then washed in TBS and incubated with Protein
Block Serum Free. Rat anti-human/mouse PNAd was
applied, followed by incubation with donkey anti-rat
IgG fluorescein isothiocyanate-conjugated (Jackson
ImmunoResearch Laboratories). After TBS washing
and an additional blocking in 10% human serum di-
luted in TBS, goat anti-human CCL21 was applied,
followed by incubations with donkey anti-goat IgG biotin-
ylated (Jackson ImmunoResearch Laboratories) and rho-
damine Red-X-conjugated streptavidin (Jackson Immu-
noResearch Laboratories). Sections were counterstained
using DAPI (4,6-diamidino-2-phenylindole) (Sigma) and
Table 1. Patients’ Characteristics
RA (n  27) SS (n  21) UC (n  10) CD (n  6)
Age (years) (mean  SD) 58.5  16 55.5  13 42.4  11.2 38.3  11.8
Female/male 22/5 21/0 3/7 2/4
Disease duration (years) (mean  SD) 10.6  7.9 1.8  1.5 5.4  4.2 6.7  4.3
ESR (mm/1 hour) (mean  SD) 32.9  22.3 16.2  9.3 37  20.5 37.8  24.4
CRP (mg/dl) (mean  SD) 1.6  2.1 0.4  0.2 2.5  2.9 2.7  3.3
No. of RF (%) 16/27 (59.2) 17/21 (80.9) ND ND
No. of anti-SSA/Ro and/or anti-SSB/La (%) 1/27 (3.7) 15/21 (71.4) ND ND
Use of corticosteroids (%) 20/27 (74.1) 0/21 (0) 9/10 (90) 4/6 (66.7)
Other immunosuppressants
Methotrexate (%) 12/27 (44.4) 0/21 (0) 0/10 (0) 0/6 (0)
Hydroxycloroquine (%) 11/27 (40.7) 6/21 (28.6) 0/10 (0) 0/6 (0)
Sulfasalazine or mesalazine (%) 0/27 (0) 0/21 (0) 8/10 (80) 3/6 (50)
Leflunomide (%) 3/27 (11.1) 0/21 (0) 0/10 (0) 0/6 (0)
Azathioprine (%) 0/27 (0) 0/21 (0) 1/10 (10) 0/6 (0)
Anti-TNF- (%) 1/27 (3.7) 0/21 (0) 0/10 (0) 1/6 (16.7)
Pathological scoring* NA 2.4  3.5 2.4  1.2 3.2  0.7
No. of samples with lymphoid aggregates (%) 15/27 (55.5) 11/21 (52.4) 5/10 (50) 3/6 (50)
No. of samples with CD21 FDC networks (%)† 5/27 (18.5) 4/21 (19) 1/10 (10) 1/6 (16.7)
RA, rheumatoid arthritis; SS, Sjögren’s syndrome; UC, ulcerative colitis; CD, Crohn’s disease; ESR, erythrocyte sedimentation rate; CRP, C-reactive
protein; RF, rheumatoid factor; ND, not determined; FDC, follicular dendritic cell. Results are expressed as mean  SD.
*Histological grading of inflammation in the SS specimens was performed according to the method of Greenspan and colleagues,56 who defined
the focus score (FS) as the number of inflammatory infiltrates of at least 50 cells present in 4 mm2 of gland surface unit. Results are expressed as
mean FS (SD). Histological grading of inflammation in the UC and CD specimens was performed according to the following 0 to 4 scale: 0, normal
mucosa; 1, no active inflammation; 2, mild active inflammation; 3, moderate active inflammation; and 4, severe active inflammation.5 Results are
expressed as mean  SD. NA, not applicable.
†Data on the prevalence of CD21 FDC networks have been obtained by a single cutting level analysis.
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mounted with fluorescence mounting medium (DAKO).
Negative staining control experiments were performed by
using a control isotype-matched antibody.
Double-color IF for CCL21 or CCL19 and CD45 or
SMA on paraffin-embedded sections were performed
analogously to IHC experiments. The following second-
ary antibodies were used: donkey anti-rat IgG fluores-
cein isothiocyanate for CD45 and SMA and donkey
anti-goat IgG biotinylated followed by amplification
with Red-X-conjugated streptavidin for CCL21 and
CCL19 (all from Jackson ImmunoResearch Laborato-
ries). All IF procedures were performed in darkness.
Sections were examined by IF microscopy (BX51;
Olympus, Hamburg, Germany) and confocal micros-
copy (Leica TCS SP2; Leica Microsystems GmbH, Wet-
zlar, Germany).
Histological Data Evaluation and Quantification
The immunocharacterization of CCL21-producing ves-
sels in RA synovium was performed on 3-m-thick
consecutive sections stained for pan-vascular markers
(CD31 and CD34),31,32 HEV markers (PNAd),33 and a
subset of markers that have been shown to be specific
for the lymphatic endothelium, including LYVE-1, po-
doplanin, and D6.34–36 Because of the heterogeneous
distribution of CCL21 vessels, quantification and im-
munophenotypic analysis were performed in CCL21
vascular hot spots or areas containing the highest
density of CCL21 vessels, according to a method first
used for the estimation of new blood vessel formation
in breast tumor.37 Three hot spots per section were
selected. In each spot, positive vessels were counted
in 10 consecutive fields at high magnification (400).
The median number of counted CCL21 vessels/sam-
ple in the nine samples with the presence of vascular
CCL21 (see Results) was 50, with a range of 30 to 202.
Of counted CCL21 vessels 99.2% were recognized
by two independent observers on serial sections
stained for vascular markers. To confirm the co-local-
ization between CCL21 and lymphatic markers on ECs,
in six samples double IF stainings for CCL21 and po-
doplanin were performed, and vessels were examined
inside and outside of hot spots.
The immunocharacterization of nonendothelial CCL21-
expressing cells as well as CCL19 cells in human SLOs
was assessed for each tissue in 10 consecutive high-
power fields (1000) (median number of counted
CCL21 cells/sample, 178; range, 86 to 242; median
number of counted CCL19 cells/sample, 83; range, 72
to 102). In RA synovium, attributable to heterogeneous
distribution of CCL21 and CCL19 cells, the analysis
was performed according to the hot spot method (me-
dian number of counted CCL21 cells/sample, 43;
range, 7 to 100; median number of counted CCL19
cells/sample, 34; range, 4 to 82).
The prevalence of CCL21SMA cells in the synovial
lymphoid tissue was evaluated in the 15 samples with
lymphoid aggregates (see Results and Table 1) and ex-
pressed as the percentage of aggregates of large dimen-
sions (radial cell count from the more centrally located
vessel to the identifiable edge of the aggregate 10
cells10) positive for CCL21 and SMA. The total number of
large-size aggregates counted was 269, with a median
number/sample of 12 (range, 3 to 44).
LN Primary Cell Separation and Cell Lines
Primary cells from one normal human MLN were obtained
by enzymatic digestion with 0.2% collagenase in high-
glucose Dulbecco’s modified Eagle’s medium (GIBCO,
Invitrogen, Carlsbad, CA) containing 10% fetal bovine
serum (GIBCO, Invitrogen) and 100 U/ml penicillin plus
100 g/ml streptomycin sulfate (GIBCO, Invitrogen). After
4 hours of incubation at 37°C, cells were collected,
washed, and used for cytospin preparations and RNA
extraction. RA synovium, spleen, and LN fibroblast cell
lines were kindly provided by Debbie Hardie (Depart-
ment of Rheumatology, Birmingham University, Birming-
ham, UK).
IF on Cytospins
Double-color IF for CCL21 and SMA on freshly isolated
cells and cell lines was performed analogously to IF
experiments on frozen tissue samples. Cells were fixed
with 2.5% paraformaldehyde for 20 minutes at room
temperature and permeabilized with TBS and 0.3%
saponin.
RNA Extraction and Quantitative
Real-Time PCR
Total RNA was extracted from isolated cells using the
RNeasy mini kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions and was reverse-transcribed
into cDNA with the ThermoScript reverse transcriptase-
PCR system (Invitrogen). Quantitative real-time PCR was
performed using Hot Start DNA polymerase (Qiagen) in
Figure 1. CCL21-producing endothelial structures in rheumatoid synovitis display lymphatic features. In situ hybridization (A) and IHC (B) for CCL21
in parallel tissue sections of rheumatoid synovial membrane demonstrate co-localization between CCL21 mRNA (A, in black) and protein (B, in red) in
a subset of vascular structures. C–G: A synovial lymphoid aggregate is shown on serial tissue sections immunostained for CCL21 (C, in red), CD31 (D,
in red), CD34 (E, in red), PNAd (F, in red), and LYVE-1 (G, in red). Arrows indicate the same vascular structures analyzed in parallel sections. Note
that all CCL21-positive vessels (black arrows) are LYVE-1-positive lymphatic vessels. H–K: IHC on sequential sections of a synovial hypertrophic
villous showing a subset of vascular structures immunostained for CCL21 (H, in red), LYVE-1 (I, in red), podoplanin (J, in red), and D6 (K, in red). All
CCL21-positive vessels (H) are LYVE-1-positive (I) podoplanin-positive (J), and D6-positive (K). The synovial vessel delimited by the black square in
H–K is shown at high magnification in L–O, demonstrating the co-localization of CCL21 (L), LYVE-1 (M), podoplanin (N), and D6 (O). P–S: High-
magnification views of serial sections of tonsil showing endothelial co-localization of CCL21 (P, in red) with LYVE-1 (Q, in red), podoplanin (R, in
red), and D6 (S, in red). T: Single color separations and color merges of double IF staining for CCL21 (in green) and podoplanin (in red) on
rheumatoid synovium, showing the co-localization of the two markers. Counterstaining with DAPI in blue. Original magnifications: 400 (A–G); 200
(H–K); 1000 (L–T).
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the presence of 0.1 SYBR Green (Molecular Probes,
Invitrogen) using an Applied Biosystem 7900HT se-
quence detector (Applied Biosystems, Foster City, CA). A
serial dilution of a cDNA from human LN was used for a
standard curve. Gene expression was calculated using
a standard curve and normalized for the expression of
the housekeeping gene -actin. Primers used were
CCL21: forward 5-CAAGCTTAGGCTGCTCCATC-3, re-
verse 5-TCAGTCCTCTTGCAGCCTTT-3; and -actin:
forward 5-CACGGCTGCTTCCAGCTC-3, reverse 5-CAC-
AGGACTCCATGCCCAG-3.
Results
CCL21-Producing Endothelial Structures in
Rheumatoid Synovitis Display Lymphatic
Features
In keeping with previous reports,5,10,11 we observed high
expression of CCL21 in ECs of vascular structures in a
proportion of RA synovial tissues. Single cutting level
analysis on paraffin sections showed the presence of
CCL21 vessels in 9 of 27 samples, whereas the ab-
sence or only the occasional presence of these struc-
tures was observed in the other specimens included in
the study. Parallel in situ hybridization and IHC experi-
ments on 3-m-thick consecutive sections demonstrated
CCL21 mRNA and protein co-localization in all vessels
analyzed (Figure 1, A and B).
The immunophenotypic analysis of CCL21-producing
vessels revealed that all were CD31, confirming their
vascular nature (Figure 1, C and D). CD34 staining was
instead variable, with some CCL21 vessels displaying
high levels of CD34 (Figure 1, C and E) and some others
being CD34-low/negative (not shown). No PNAd expres-
sion was found in ECs of CCL21 vascular structures
(Figure 1, C and F). Notably, LYVE-1 (a marker of the
lymphatic endothelium) stained 100% of CCL21-produc-
ing vessels (Figure 1, C and G) and, vice versa, CCL21
expression was recognized in 97.6  1.2% (mean  SD)
of LYVE-1 vessels. Conversely, CD31CD34LYVE-1-
negative vessel did not reveal definite CCL21 expression
in the cytoplasm of ECs, showing only occasionally a
weak and poorly defined CCL21 signal. To confirm the
identity of CCL21LYVE-1 vessels as lymphatics, we
stained consecutive sections with antibodies against po-
doplanin and D6. These experiments clearly demon-
strated that all CCL21LYVE-1 vessels also displayed
podoplanin immunoreactivity (Figure 1, H–J and L–N)
and that some of them were also positive for D6, although
all D6 vessels were CCL21LYVE-1podoplanin (Fig-
Figure 2. The lymphatic nature of CCL21 endothelial structures is a
shared feature of different human chronic inflammatory diseases. Serial
immunostaining for CCL21 (A, C, E, and G; in red) and LYVE-1 (B, D, F,
and H; in red) is shown on sections of lichen planus (A and B), SS (C and
D), UC (E and F), and CD (G and H). All CCL21-positive vessels are
LYVE-1-positive. Black arrows indicate the same vascular structures
analyzed in parallel sections. Note that CCL21-expressing vessels are
LYVE-1-positive both in tissue areas characterized by dense immune-cell
infiltration with lymphoid aggregates (E and F) and in noninfiltrated areas
(G and H). Original magnifications, 200.
Figure 3. Distribution of periendothelial CCL21 cells in HEVs of ectopic
GC-like structures. Serial immunostaining for CD21 (A), CXCL13 (B), CCL21
(C), and PNAd (D) is shown on tissue sections of rheumatoid synovium,
illustrating the presence of CCL21-expressing cells localized perivascularly
(C) in close association to PNAd-positive HEVs (E) within a highly organized
aggregate characterized by a CD21 follicular DC network (A) and CXCL13
expression (D). In E and F, a detail of the vessel delimitated by the black
square in C and E is shown at high magnification, revealing the presence of
CCL21-expressing non-ECs (D) adherent to the abluminal side of the PNAd-
positive HEV endothelium (F). Original magnifications: 200 (A–D); 1000
(D and F).
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ure 1, H–K and L–O). Results were confirmed by double
IF staining for CCL21 and podoplanin, showing podopla-
nin staining in 100% of CCL21 vessels independently of
their size and their location within the synovial tissue
(Figure 1T).
To exclude that synovial blood vessel ECs aberrantly
expressed CCL21 only in tissues with organized lym-
phoid aggregates, we analyzed our samples for the pres-
ence of specific lymphoid tissue-like features (T-B cell
compartmentalization and CD21 follicular DC net-
works). These experiments confirmed that CCL21 ves-
sels both in synovial tissues with diffuse infiltration (n 
12/27, 44.4%) and in those with lymphoid aggregates,
with (n  5/27, 18.5%) or without (n  10/27, 37.1%)
detectable germinal centers (GCs), were 100% positive
for LYVE-1 and podoplanin. Similarly, in tonsil paraffin
sections, CCL21 was found in the cytoplasm of LYVE-
1podoplanin ECs displaying variable D6 expression
(Figure 1, P–S).
The Lymphatic Nature of CCL21 Endothelial
Structures Is a Shared Feature of Different
Human Chronic Inflammatory Diseases
To test whether the findings obtained in RA synovitis are
applicable to other human chronic inflammatory condi-
tions, we extended the immunocharacterization of CCL21
vessels to other inflamed tissues. All CCL21 endothelial
structures were LYVE-1 both in psoriasis (not shown)
and in lichen planus (Figure 2, A and B), two autoimmune
skin inflammatory diseases in which lymphoid neogene-
sis does not commonly occur. The same findings were
observed in SS (Figure 2, C and D), UC (Figure 2, E and
F), and CD (Figure 2, G and H), where a lymphoid neo-
genetic organization can be prominent (Table 1). Again,
CCL21 endothelial structures were 100% LYVE-1 irre-
spectively to their localization and association with the
ELT. The observed CCL21 expression by the lymphatic
Figure 4. Preserved relationship between CCL21 production and HEVs in human SLOs and ELTs. A–J: Immunostaining for CCL21 (A, C, E, G, and I; in red) and
parallel immunostaining for PNAd (B, D, F, H, and J; in red) on paraffin-embedded tissues of human MLN (A and B), SS salivary gland (C and D), UC intestinal
wall (E and F), CD intestinal wall (G and H), and RA synovium (I and J) reveal the presence of CCL21-expressing non-ECs adherent to the abluminal side of
PNAd-positive HEVs both in human SLOs and within ectopic lymphoid aggregates in lymphoid neogenetic diseases. K and L: IHC (K) and in situ hybridization
(L) for CCL21 in consecutive synovial tissue sections of RA confirm the complete co-localization between CCL21 protein expression (K, in red) and mRNA
production (L, in black) within non-ECs surrounding a vessel with HEV morphology. Black arrows indicate blood vessel ECs lacking detectable levels of CCL21,
despite the presence of adjacent CCL21-positive cells. M and N: Single color separations and color merges of double IF staining for CCL21 (in red) and PNAd (in
green) on cryosections of human tonsil (M) and rheumatoid synovial tissue (N). The strongest CCL21 immunostaining is seen within PNAd-positive HEVs at their
basal side, whereas PNAd staining is strongest at the luminal face. Original magnifications: 1000 (A–J, M, and N); 400 (K and L).
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Figure 5. SMA-positive stromal cells express CCL21 in human MLNs and in synovial ELT. Left: Stainings on paraffin-embedded sections of human MLN are shown.
A and B: IHC for PNAd (A, in red) and double IHC for SMA (B, in brown) and CCL21 (B, in red) on serial tissue sections showing CCL21-positive cells in
periendothelial localization around a PNAd-positive HEV and displaying SMA immunoreactivity. C–E: Single color separations (C and D) and double merge (E) of
double IF for CCL21 (C and E; in red) and SMA (D and E; in green) show the co-localization between the two antibodies (revealed by yellow signal in E) in
association to a vessel with HEV morphology. F: Double IHC for CCL21 (in red) and SMA (in brown) is shown on a tissue area at low magnification, demonstrating
the co-localization between CCL21 and a network of SMA-positive cells distributed throughout the T area and connecting vascular structures. Note the absence of
the SMA-positive reticulum inside a germinal center (black arrow). In G, a detail of the area represented in F is shown at high magnification. H–J: Single color
separations (H and I) and color merge (J) of double IF for CCL21 (H and J; in red) and SMA (I and J; in green) show the co-localization between CCL21-expressing
cells within the T-cell area and SMA-positive reticular cells, as revealed by yellow signal in J. Right: Stainings on paraffin-embedded sections of rheumatoid synovial
membrane are shown. K and L: single IHC for PNAd (K, in red) and double IHC for SMA (L, in brown) and CCL21 (L, in red) on serial sections show that CCL21-
positive cells adherent to a PNAd-positive HEV are SMA-positive. M–O: Single color separations (M and N) and color merge (O) of double IF for CCL21 (M and O;
in red) and SMA (N and O; in green) confirms the co-localization of the two markers (yellow signal in O) in association to a synovial vessel with HEV morphology.
P: Double IHC for CCL21 (in red) and SMA (in brown) is shown at low magnification on a synovial hypertrophic villous, demonstrating the co-localization between
CCL21 and a network of SMA-positive cells connecting vascular structures within a lymphoid aggregate. In Q, high magnification of a detail of picture P is shown.
R–T: Single color separations (R and S) and color merge (T) of double IF for CCL21 (R and T; in red) and SMA (S and T; in green) confirms the co-localization of
the two markers (yellow signal in T) within reticular cells unrelated to vascular structures. Experiments analyzed under IF microscopy. Original magnifications:
1000 (A–E, G–O, and Q–T); 200 (F and P).
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endothelium was consistent with results obtained in non-
inflamed peripheral tissues (normal synovium, colon, and
skin), where CCL21 vessels revealed intense staining
for LYVE-1 (not shown). The above results demonstrate
that inflammation and ectopic lymphoid neogenesis can
take place in the absence of aberrant induction of CCL21
in blood vessels and that lymphatics can be the exclusive
endothelial source of CCL21 in ELTs as well as in SLO.17
The Peri-HEV Synthesis of CCL21 Is
Reprogrammed in ELTs
Although CCL21 production was not detected in HEV
ECs, in some lymphoid aggregates in SS, UC, CD, and
RA, CCL21-expressing cells were recognized in an ex-
travascular location, sometimes tightly adherent to the
basal side of a proportion of PNAd HEV. This pattern
was also identified inside highly organized lymphoid
clusters as inferred by the presence of follicular DC net-
works and CXCL13 expression (Figure 3). Parallel in situ
hybridization experiments confirmed the lack of detect-
able levels of CCL21 mRNA in ectopic HEV endothelium,
even when surrounded by high numbers of CCL21-pro-
ducing cells, which demonstrated stringent matching be-
tween CCL21 mRNA and protein expression (Figure 4).
Periendothelial CCL21 was highly restricted to lymphoid
aggregates in all tissues and diseases analyzed and was
reminiscent of the distribution of CCL21-expressing cells
observed in human tonsils and LNs on paraffin sections.
Figure 4, A–J, illustrates the consistency of CCL21 peri-
HEV expression between human SLOs and the ELT in SS,
UC, CD, and RA. Figure 4, K and L, shows the co-
localization of CCL21 protein and mRNA in ELTs. As a
proof of the strong association between this pattern with
inflammation and lymphoid tissue organization (both ec-
topic and orthotopic), we could not observe any perivas-
cular expression of CCL21 in psoriasis, lichen planus,
and noninflamed control tissues including normal syno-
vium, minor salivary glands, colon, and skin (not shown).
To allow a comparison with formalin-fixed tissues, we
performed double IF stainings for CCL21 and PNAd on
cryosections. These experiments showed CCL21 protein
within and at the basal side of HEVs in human SLOs
(Figure 4M), in accordance to the recent findings from
Carlsen and colleagues.17 The same pattern was con-
firmed in some HEVs of RA lymphoid neogenetic lesions
(Figure 4N). Taken together, these results demonstrate
that the anatomical relationship between CCL21 and the
vascular system is qualitatively preserved in SLOs and
ELTs, suggesting the existence of a conserved cellular
program regulating CCL21 expression in human lym-
phoid tissues.
SMA Stromal Cells Express CCL21 in
Peri-HEV Location and in T-Cell-Rich Areas
Both in ELTs and Human SLOs
To characterize the nature of extra-endothelial CCL21-
expressing cells in human SLOs and ELTs, we performed
double IHC and IF staining on paraffin-embedded sam-
ples. To provide direct evidence of the hematopoietic or
stromal nature of CCL21-producing cells, we first exam-
ined CCL21 and CD45 staining. These experiments dem-
onstrated that, in human LNs and tonsils, all CCL21
cells in close proximity to vascular structures with HEV
morphology were CD45-negative. CD45-negative, CCL21
stromal cells were also found scattered within the T-cell
areas and unrelated to HEVs. Interestingly, identical re-
sults were obtained in RA synovium ELTs, where CCL21
cells inside the aggregates were mostly CD45-negative,
Figure 6. Intracytoplasmic localization of CCL21 in SMA-positive cells. A–D:
Double IF for CCL21 (in red) and SMA (in green) is shown in human MLN (A
and B) and rheumatoid synovial membrane (C and D) analyzed by confocal
microscopy. B and D show the images represented in A and B with DAPI
counterstaining to highlight the cell nucleus (in blue). CCL21 signal is de-
tected within SMA-positive reticular cells both in human SLOs and in the ELT
of rheumatoid synovitis. E–H: Single color separations (E and F) and color
merges (G and H) of double IF staining for CCL21 (E, G, H, in red) and SMA
(F–H, in green) on a cytospin preparation obtained from freshly isolated LN
cells, demonstrating co-localization of CCL21 and SMA ex vivo in two cells
indicated by white arrows (yellow signal in G and H). In H, cell nuclei are
counterstained in blue with DAPI. Arrowheads indicate a SMA-positive cell
lacking CCL21 staining. I: CCL21 gene expression levels in intact LN, in the
freshly isolated lymph node cells analyzed in E–H (LN FIC), and in a lymph node
fibroblast cell line (LN CL) determined by quantitative PCR. RQ, relative quan-
tification. Data are normalized for -actin. Original magnifications, 1000.
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both in peri-HEV location and scattered within lymphoid
clusters (not shown).
Morphologically, most of CD45-negative CCL21
cells both in human SLOs and in ELTs were character-
ized by a spindle-shaped or irregular cell body with
branching processes. This pattern is strongly reminis-
cent to that of fibroblastic reticular cells (FRCs), peri-
cytes, and myofibroblasts, different subsets of mesen-
chymal cells capable to trans-differentiate one into
another38,39 and sharing the expression of SMA.40–42
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We thus performed double IHC and IF experiments for
CCL21 and SMA in SLOs and ELTs. In human LNs from
various anatomical districts (mesenteric, cervical, axil-
lary), we observed stringent co-localization of perien-
dothelial CCL21 and SMA in all areas examined (Figure
5, A–E). Furthermore, CCL21 cells scattered within
the T-cell area co-localized with a meshwork of SMA
dendritiform cells extending from the subcapsular si-
nus and disseminated throughout the node, where they
created a connection among HEVs (Figure 5, F–J).
Altogether, CCL21-expressing cells were 92.7  3.4%
(mean  SD) SMA in MLNs, 88.2  1.2% in CLNs,
and 84.2  1% in ALNs. Similar co-localization was
demonstrated in spleen (89.5%) and in tonsils, al-
though in the latter the SMA meshwork appeared less
developed and CCL21 cells lacked SMA staining in
certain tissue areas (29.3  15%). No co-localization
was observed between T-cell area SMA cells and
LYVE-1 in all SLOs analyzed (not shown).
Results in RA ELT were consistent with those ob-
tained in human LNs. Indeed, peri-HEV CCL21-ex-
pressing cells were all SMA (Figure 5, K–O), and SMA
immunoreactivity was also demonstrated in LYVE-1-nega-
tive, CCL21 cells scattered within lymphoid aggregates.
Altogether, 94.7  6% of CCL21-expressing cells exhib-
ited SMA staining. CCL21SMA cells were recognized
in 150 of 269 (55.8%) large aggregates (median percent-
age of positive aggregates/sample, 66.7%; range, 12.5 to
100%), their presence not being strictly related to GC
follicles. Although most of these cells were either isolated
or organized in small clusters (Figure 5H), the constitution
of a more developed LN-like CCL21SMA meshwork
connecting vascular structures could be demonstrated in
a proportion of large-size aggregates (Figure 5, P–T). The
analysis of lymphoid neogenetic lesions in SS, UC, and
CD revealed the presence of SMA CCL21-expressing
cells also in these pathological settings. In normal control
tissues, instead, no periendothelial or scattered expres-
sion of CCL21 was found despite the presence of SMA
cells in perivascular location (not shown).
Confocal microscopy examinations confirmed
CCL21 localization in the cytoplasm of SMA cells both
in SLOs and RA ELTs (Figure 6, A–D). CCL21 staining
was also observed in freshly isolated SMA cells ob-
tained after LN enzymatic digestion and analyzed at
the single-cell level on cytospin preparations (Figure 6,
E–H). Parallel experiments by quantitative PCR on the
same cells confirmed local expression of CCL21 mRNA
(Figure 6I). Conversely, despite the presence of SMA
cells between passages 6 and 10, no significant
CCL21 expression was recognized in LN, spleen, and
RA synovium fibroblastic lines either in basal condi-
tions or on stimulation with tumor necrosis factor- and
lymphotoxin 12 throughout 72 hours.
SMA Cells in Human SLOs and ELTs Express
CCL19 and Co-Localize with Mature DCs
To compare additional features of SMA cells in SLOs
and ELTs, we investigated the expression of CCL19, the
other known ligand for CCR7, which has been previously
reported in FRCs in murine SLOs.15 Interestingly, double
IHC and IF experiments revealed the capacity of SMA
cells both in SLOs and in RA synovium ELT to express
CCL19 (Figure 7, A–H), providing further evidence that
the constitutive cellular properties of SLO stroma are
reprogrammed in inflammatory ELT. Altogether, 91.7 
5.2% (mean SD) of CCL19 cells were SMA in human
LNs (MLNs, CLNs, and ALNs), and 30.3  7.4% of
CCL19 expressed SMA in RA ELT, where double-posi-
tive cells were closely associated to the blood vascular
endothelium, whereas CCL19SMA cells were mostly
scattered within the aggregates.
In keeping with Page and colleagues,11 SMACCL21
cells in synovial ELT were found in close association to
DC-LAMP mature DCs, which are known to express
CCR7,43 suggesting a role for the ectopic stroma through
the production of lymphoid chemokines in the regulation
of local immune interactions (Figure 7I). Supporting this
concept, despite synovial lymphatics appearing fre-
quently devoid of cells, DC-LAMP mature DCs were
also demonstrated around and in the lumen of a propor-
tion of CCL21 LYVE-1 vessels in the inflamed sublining
(Figure 7, J and K).
Discussion
In this article, we provide evidence that, as in human
SLOs, CCL21 endothelial production in chronically in-
flamed tissues is confined to the lymphatic apparatus
and that neither flat-walled blood vessels nor HEVs of
ELTs produce detectable levels of the chemokine. Our
data demonstrate that the expression pattern of CCL21
within the blood vascular system is conserved across the
spectrum of human lymphoid tissues, being associated
with peri-ECs. This lends further support to the notion of
the existence of conserved programs regulating lym-
phoid structural organization in homeostasis and inflam-
mation. In keeping with this concept, we demonstrate that
Figure 7. SMA-positive can express CCL19 and co-localize with mature DCs. A–D: Stainings on paraffin-embedded sections of human MLN are shown. A:
Double IHC for CCL19 (in red) and SMA (in brown) is shown on a tissue area at high magnification, demonstrating the co-localization between CCL19 and a
network of spindle-shaped SMA-positive cells distributed throughout the T area. B–D: Color merge (B) and single color separations (C and D) of double IF
for CCL19 (B and C; in red) and SMA (B and D; in green) confirm the co-localization between CCL19-expressing cells within the T-cell area and SMA-positive
reticular cells, as revealed by yellow signal in B. E–H: Stainings on paraffin-embedded sections of rheumatoid synovial membrane are shown. E: Double IHC
for CCL19 (in red) and SMA (in brown) reveals co-localization between CCL19 and SMA within perivascular cells in a lymphoid aggregate, indicated by black
arrows. Some scattered CCL19-expressing cells are SMA-negative (arrowheads). F–H: Color merge (F) and single color separations (G and H) of double IF
for CCL19 (F and G; in red) and SMA (F and H; in green) confirm the co-localization between CCL19-expressing and SMA-positive cells, as revealed by
yellow signal in F. Note again CCL19-positive SMA-negative cells (arrowheads). I–K: Double IHC for CCL21 (in red) and the mature DC marker DC-LAMP
(in brown) in rheumatoid synovium sections. I: In lymphoid aggregates, perivascular CCL21-expressing cells show area co-localization with DC-LAMP-
positive DCs. DC-LAMP-positive DCs are also found in proximity (J) and within (K) CCL21-positive lymphatic vessels in synovial areas of cell infiltration.
Original magnifications, 1000.
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extra-endothelial CCL21 is expressed by stromal cells
displaying a myofibroblast-like phenotype both in human
SLOs and ELTs.
The characterization of CCL21-producing vessels per-
formed in this work relies on the use of a combination of
markers specific for the lymphatic endothelium that have
recently become available, such as LYVE-1,34 podopla-
nin,35 and D6.36 CCL21 vessels in RA synovitis all ex-
pressed LYVE-1 and podoplanin, irrespectively to their
localization and association with the ELT. They also were
CD3131,32 and displayed variable levels of CD34, a
pan-vascular marker that is often absent from normal
tissue lymphatics but can be up-regulated in certain
pathological conditions, such as in tumor-associated
lymphangiogenesis.44 The combinatorial phenotype that
we report here clearly indicates the lymphatic nature of
CCL21 vascular structures. In keeping with this, we
demonstrated that synovial CCL21 lymphatics can ex-
press variable levels of D6, a lymphatic promiscuous
chemokine receptor that functions as a scavenger recep-
tor for the internalization and neutralization of inflamma-
tory chemokines.36,45
By demonstrating the lymphatic nature of CCL21-pro-
ducing vessels in a subset of inflamed peripheral tissues
from different diseases and of different embryological
origin, we provide evidence that chronic inflammation
and ectopic lymphoid neogenesis are not intrinsically
associated with aberrant up-regulation of CCL21 in blood
vessel and HEV endothelium. This result is in keeping
with the notion that human SLO HEVs, differently from
mouse, do not synthesize the chemokine10,17 and sug-
gests the existence of a common organizational program
active in human SLOs and ELTs. Supporting this point of
view, our data indicate that, inside ectopic lymphoid ag-
gregates of inflamed peripheral tissues, the distribution of
CCL21 reproduces the anatomical relationship with HEVs
characterizing human SLOs,10,17 with periendothelial lo-
calization of CCL21-producing cells and possible luminal
localization of the protein through transcytosis.17 Passive
absorption or transcytosis might thus explain the deco-
ration of some blood vessels with CCL21 that was noticed
here and in previous reports when frozen sections are
used46–48 and justify the presence of naı¨ve cells demon-
strated in inflammatory sites.5 It should be emphasized
that our results do not exclude that a low rate of CCL21
transcription can be present in inflamed blood vessels,
as postulated by Carlsen and colleagues17 in SLO HEV.
However, the data reported here, based on the analysis
of different tissues from different diseases, demonstrate
that the level of expression of CCL21 in the blood vascu-
lar compartment is similar between SLOs and ELTs and
that aberrant up-regulation of CCL21 in the blood vessel
endothelium is not a systematic feature of human chronic
inflammation.
One of the main differences between SLOs and ELTs is
the fact that, whereas SLOs also function to maintain
immunosurveillance under homeostatic conditions, ELT
development and function is triggered by pathological
and immunological stimuli. We thus considered the pos-
sibility that, although CCL21-producing cells share a sim-
ilar relationship with T cells and HEVs, the cellular
sources of the chemokine could be different in terms of
their stromal or hematopoietic origin in SLOs and ELTs.
Our data demonstrate that CCL21 is expressed by
CD45, SMA cells both in SLOs and ELTs, indicating a
common stromal origin of these cellular subsets. This
pattern, which constituted the bulk of CCL21 expression
in human LNs and in RA ELT, was less developed in
tonsils where CCL21 SMA-negative cells were fre-
quently observed, indicating that myofibroblast precur-
sors or other cell types, such as DCs, may contribute to
CCL21 production in specific conditions.14,46,49 The ex-
istence of additional levels of regulation controlling SMA
and CCL21 expression was also emphasized by the fact
that both in normal as well as in inflamed tissues SMA
cells can be recognized in the absence of CCL21.
Our data, combined with previous observations in
mice,15 also provide evidence that, differently from ECs,
the extravascular cellular sources of CCL21 are not only
conserved across human lymphoid tissues but also
across species. Indeed, it has been shown that in murine
SLOs, the cell type responsible for CCL21 production is
represented by gp38 FRCs that ensheathe the mesh-
work of collagen fibers (lymphoid reticular network) ex-
tending from the capsule throughout the node and encir-
cling HEVs15 and providing a tight regulation of
chemokine and antigen delivery within SLOs.40,50 Further
studies have shown that murine FRCs also express
CCL19,15 ERTR7,51 desmin, and SMA,40 a reliable
marker of myofibroblasts.42 Although the specific fea-
tures of this apparatus in human SLOs have been less
extensively investigated,39,52 our observations strongly
indicate that CD45, CCL21, SMA fibroblastoid cells,
which we have identified in human SLOs, represent FRCs
as suggested by their phenotypic marker expression,
their dendroid morphology, and their reticular distribution
throughout the T area and among the subcapsular sinus
and HEVs. The inability to detect CCL21 expression in
human SLO SMA fibroblast cell lines in basal conditions
or on in vitro stimulation with tumor necrosis factor- and
lymphotoxin, which have been shown to be required for
normal expression of CCL21 in mouse spleen,53 is in
keeping with previous reports in murine LN FRCs.51 This
suggests that human myofibroblast-like cells may lose
the capacity to express CCL21 because of in vitro trans-
differentiation or, alternatively, that cell-contact-depen-
dent interactions are required for the process to take
place.
To our knowledge, no data at present demonstrate the
possible developmental plasticity of the FRC network in
human ELTs, despite experimental models of ectopic
lymphoid neogenesis indicating that gp38 and ERTR7
stromal cell networks can arise ectopically, such as in the
pancreas of CCL21 and CXCL13 transgenic mice.7,54
The recognition that the stromal scaffold of the ELT in RA
can acquire CCL21, CCL19, and SMA expression asso-
ciated with the organization in an intra-aggregate mesh-
work connecting and encircling vascular structures indi-
cates that a vestige of the lymphoid FRC network can be
induced in human inflammation. Consistent with this, in-
creased myofibroblast conversion has been reported in
synovial fibroblasts derived from high-inflammation tis-
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sues in association to high expression of T cell/B cell and
antigen-presenting cell genes.55 Further ultrastructural
studies are required to understand the actual compe-
tence of SMA fibroblastoid cells to organize functional
networks and mediate antigen and chemokine delivery in
human inflammatory ELTs.
In conclusion, our results indicate that CCL21 produc-
tion in inflamed tissues is promoted by amplification of
physiological mechanisms and ectopic reprogramming
of SLO constitutive bioactivities. Our data, combined with
the recent demonstration of the co-stimulatory capacity of
CCL21 in T-DC interactions,4 also emphasize the role of
the tissue stroma as a third actor in the constitution of the
immunological synapsis in human lymphoid tissue, sug-
gesting the mechanisms of lymphatic and smooth mus-
cle-positive myofibroblast differentiation in inflammation
as a possible tool to interfere specifically with peripheral
adaptive immune responses.
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